Targeting Glycolytic Plasticity to Overcome Therapy Resistance in Cancer Stem Cells: Mechanisms and Clinical Perspectives
Cells · 2026
DOI: 10.3390/cells15121107 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Jiaxin Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Drug Resistance, Neoplasm, Glycolysis, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chengdu University of Traditional Chinese Medicine, Xinglin Scholar Program—Postdoctoral Special Fund of Chengdu University of Traditional Chinese Medicine.
Abstract (Originalsprache)
Cancer stem cells (CSCs) constitute a resilient tumor subpopulation responsible for multidrug resistance, metastasis, and clinical relapse. A cardinal hallmark of these cells is profound metabolic plasticity. This dynamic defense mechanism facilitates rapid shifts between glycolysis, oxidative phosphorylation (OXPHOS), and alternative nutrient catabolism, enabling CSCs to bypass microenvironmental constraints. This review delineates how glycolytic adaptation functions as a primary driver of therapy resistance within the CSC niche. We dissect the regulatory triad controlling these metabolic shifts, which includes rate-limiting enzymes, epigenetic and epitranscriptomic remodeling, and master transcription factors. Glycolytic reprogramming transcends bioenergetics by acting as a metabolic signaling node. It integrates with the epithelial–mesenchymal transition (EMT) program, autophagic pathways, and the immunosuppressive tumor microenvironment (TME) to fortify CSC survival. We appraise emerging therapeutic interventions targeting these metabolic vulnerabilities. Strategies focus on optimizing small-molecule inhibitors, nanotechnology-enabled delivery systems, and immunometabolic combination regimens. This review establishes a conceptual framework for precision interventions aimed at disrupting CSC plasticity, overcoming therapeutic resistance, and preventing tumor recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Förderung
- National Natural Science Foundation of China
- Chengdu University of Traditional Chinese Medicine
- Xinglin Scholar Program—Postdoctoral Special Fund of Chengdu University of Traditional Chinese Medicine
Zitieren
APA
Huang, J., Yang, X., Li, F., Li, X., Wei, H., & Li, M. (2026). Targeting Glycolytic Plasticity to Overcome Therapy Resistance in Cancer Stem Cells: Mechanisms and Clinical Perspectives. Cells. https://doi.org/10.3390/cells15121107
Vancouver
Huang J, Yang X, Li F, Li X, Wei H, Li M. Targeting Glycolytic Plasticity to Overcome Therapy Resistance in Cancer Stem Cells: Mechanisms and Clinical Perspectives. Cells. 2026. doi:10.3390/cells15121107
BibTeX
@article{Huang2026,
author = {Huang, Jiaxin and Yang, Xinyu and Li, Feiyu and Li, Xinyu and Wei, Hao and Li, Muyao},
title = {Targeting Glycolytic Plasticity to Overcome Therapy Resistance in Cancer Stem Cells: Mechanisms and Clinical Perspectives},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15121107}
}
EUVIMED